Your session is about to expire
← Back to Search
NG101 Gene Therapy for Age-Related Macular Degeneration
Study Summary
This trial will test if gene therapy can safely and effectively treat wet age-related macular degeneration.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My vision in the study eye is between 20/63 and 20/400, mainly due to wet AMD.My study eye has had a retinal detachment.I have had eye melanoma in the past.My vision loss is not due to AMD but another cause.My eye condition cannot improve due to severe damage in the center of my retina.I have had gene therapy in my affected eye.I am able to understand and provide consent for my participation in the study.I do not have any diabetic eye diseases or other serious eye conditions.I've had 3 or more anti-VEGF injections in one eye within the last 6 months.I have a known genetic eye disease.I have an eye condition that needs treatment or prevents a full eye exam.I am using effective birth control or am not able to have children, and I have a negative pregnancy test.I am between 50 and 89 years old with a specific type of wet age-related macular degeneration.I have had cataract surgery in the eye being studied.I am willing and able to follow the schedule for all my follow-up visits and evaluations after surgery.I have severe glaucoma not controlled by medication.I have a history of HIV, active tuberculosis, or syphilis.I haven't had eye surgery in the last 6 months.I have had radiation treatment near my eye.I have had eye surgery for glaucoma or similar conditions.I am on necessary anticoagulant therapy that can't be stopped for the NG101 injection, except for low-dose aspirin.I have had photodynamic or laser therapy for wet AMD.I haven't had any eye injections except for anti-VEGF in the last 6 months.I do not have severe health issues that would interfere with the study.
- Group 1: NG101 Gene Therapy Group 1
- Group 2: NG101 Gene Therapy Group 2
- Group 3: NG101 Gene Therapy Group 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this scientific study recruiting participants of advanced age?
"This study is enrolling individuals aged over 50 and under 89."
Are there any available vacancies in this clinical trial?
"The information provided by clinicaltrials.gov does not indicate that this treatment trial is actively recruiting at the present moment in time. It was originally posted on August 1st, 2023 and has been revised most recently on August 2nd, 2023. However, 172 other medical trials are currently seeking volunteers for their research projects."
Do I qualify to join this clinical trial?
"This clinical trial, which is accepting a total of 18 participants, requires candidates to be afflicted with age-related macular degeneration and aged between 50 and 89."
Share this study with friends
Copy Link
Messenger